首页>
外国专利>
APPLICATION OF CNP-22 SEPARATELY OR IN COMBINATION WITH PHYSALEMINE AS A THERAPEUTIC MEDICINE
APPLICATION OF CNP-22 SEPARATELY OR IN COMBINATION WITH PHYSALEMINE AS A THERAPEUTIC MEDICINE
展开▼
机译:CNP-22的单独应用或与草胺碱联合应用作为治疗药物
展开▼
页面导航
摘要
著录项
相似文献
摘要
1. The combination of the peptides Gly-Leu-Ser-Lys-Gly-Cys-Phe-Gly-Leu-Lys-Leu-Asp-Arg-Ile-Gly-Ser-Met-Ser-Gly-Leu-Gly-Cys-OH and Pyr-Ala-Asp-Pro-Asn-Lys-Phe-Tyr-Gly-Leu-Met-NH2 or their salts or hydrates. ! 2. The combination according to claim 1, where the peptides are contained in combination in an amount of from 30% by weight to 70% by weight to 70% by weight to 30% by weight. ! 3. The combination according to claim 1 for use in medicine. ! 4. Use of the peptide Gly-Leu-Ser-Lys-Gly-Cys-Phe-Gly-Leu-Lys-Leu-Asp-Arg-Ile-Gly-Ser-Met-Ser-Gly-Leu-Gly-Cys-OH or combinations according to claim 1, or 2, or 3 to obtain a pharmaceutical composition for the treatment and / or prevention of a malignant tumor, autoimmune diseases, fibrosis, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and blood vessel diseases and metabolic diseases. ! 5. The use of the peptide according to claim 4, where the malignant tumor, autoimmune disease, fibrosis, inflammatory disease, neurodegenerative disease, infectious disease, lung disease, heart and vascular disease or metabolic disease are selected from AIDS, AIDS-associated diseases, HIV, asthma , Omenn's syndrome, idiopathic pulmonary fibrosis and atopic disorders in genetically susceptible individuals. ! 6. The use of the peptide Gly-Leu-Ser-Lys-Gly-Cys-Phe-Gly-Leu-Lys-Leu-Asp-Arg-Ile-Gly-Ser-Met-Ser-Gly-Leu-Gly-Cys-OH for obtaining a composition for oral administration to newborns, toddlers and / or preschool children. ! 7. The use of the peptide Gly-Leu-Ser-Lys-Gly-Cys-Phe-Gly-Leu-Lys-Leu-Asp-Arg-Ile-Gly-Ser-Met-Ser-Gly-Leu-Gly-Cys-OH for obtaining a lyophilized composition or a buffer liquid composition. ! 8. A pharmaceutical composition containing a combination according to claim 1, at least in conjunction with one pharmaceutically acceptable carrier, cryoprotectant, l�
展开▼